Literature DB >> 2193109

Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.

D Ben-Shachar1, M B Youdim.   

Abstract

The recent studies on the chemical pathology of Parkinson's disease show selective increases of iron and lipid peroxidation and decreased glutathione (GSH) oxidizing capacity in the substantia nigra (SN). These changes are indicative of oxidative stress, possibly due to the accumulation of iron in the SN. It is the melaninized dopamine neurons that are vunerable to degeneration. The investigation of the interaction of iron with dopamine melanin demonstrates the presence of two relatively high affinity binding sites for 59Fe3+ on dopamine melanin. Interaction of Fe3+ with dopamine melanin results in potentiation of lipid peroxidation of rat cerebral cortex as compared to that induced by Fe3+. Only compounds with the ability to chelate iron are able to inhibit the binding of Fe3+ to melanin and the resultant lipid peroxidation. Therapeutic use of iron chelators, with the ability of crossing the blood brain barrier, as agents for retarding the oxidative stress and Parkinson's disease is envisaged.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193109     DOI: 10.1007/978-3-7091-9050-0_24

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  4 in total

Review 1.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

2.  The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.

Authors:  Yotam Sagi; Noam Driguès; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

Review 4.  Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Authors:  Manfred Gerlach; Kay L Double; Dorit Ben-Shachar; Luigi Zecca; Moussa B H Youdim; Peter Riederer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.